Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and DESR
NCT02204410Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2014
- Primary completion
- May 2016
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial in attention deficit hyperactivity disorder (ADHD), sponsored by Massachusetts General Hospital. Primary endpoints: Emotional Control Subscale of the Behavior Rating Inventory of Executive Function - Parent Form at 12 weeks and Clinical Global Impression Improvement for Deficient Emotional Self-Regulation at 12 weeks. Started Jul 2014; status: completed.
02
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02204410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204410.